Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme – P4HA1 prolyl hydroxylase ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, ...

Cancer therapies do not always succeed in eliminating tumor cells. Some of these cells enter a state of senescence—a latent, ...

A new generation of cancer therapies has emerged over the past few decades, including checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies that modify or directly use T-cells ...

Although targeting Tregs to restore anti-tumor immunity is an emerging area in cancer therapy, systemically inhibiting Tregs ...

Study uncovers how Cancer-associated Fibroblasts influence tumour immunity, paving the way for targeted cancer treatments.

Fortunately, the high functional specialization of cDC1s means that few of these cells are required to be present in tumors—approximately 0.1%—to achieve effective anticancer immunity.

These axes of regulation are crucially important in shaping the immune system when it is activating in metabolically demanding environments, such as tumor tissue. Indeed, the immune response to cancer ...

Researchers identify distinct molecular and immune profiles that impact the prognosis of patients with metastatic pancreatic ductal adenocarcinoma.

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...